Global Startup and Venture Capital News as of January 31, 2026: Major Funding Rounds, Venture Fund Activity, AI Investments, and Key Technology Trends for Investors.
The beginning of 2026 shows a continuation of the upward trend in the global startup and venture capital market. Following last year’s investment growth, venture funds and corporations are once again actively investing in promising companies. Major investors are forming record funds, and tech startups around the world are closing funding rounds worth hundreds of millions of dollars, despite a more selective approach to projects. Capital remains particularly focused on artificial intelligence, biotechnology, green and strategic technologies that have the potential to shape the future of industries and national security. Below is an overview of key news from the startup and venture investment world as of January 31, 2026.
The Venture Market on a Growth Wave After a Successful 2025
The global venture market enters 2026 on an optimistic note. According to industry analysts, investment in startups significantly rebounded in 2025 compared to the previous downturn. For instance, in North America, startups raised about $280 billion in venture capital over the year, up nearly 46% from the prior year. The primary driver of growth has been the boom in artificial intelligence projects — AI startups accounted for the lion's share of the capital raised. Venture investors worldwide are once again eager to invest in innovative companies, especially in breakthrough sectors. The first weeks of 2026 confirm this trend: since early January, numerous large deals and the launch of new funds have been announced, signaling a sustained positive dynamic in the venture market.
Andreessen Horowitz Attracts Record Mega Fund
One of the most notable indicators of investor confidence has been the unprecedented new fund from Silicon Valley firm Andreessen Horowitz (a16z). The company announced it raised over $15 billion for several new venture funds with various focuses — a record amount for a16z and one of the largest in the history of the venture market. The funds are allocated across several vehicles: approximately $6.75 billion is earmarked for late-stage growth investments, around $1.2 billion is directed towards the specialized American Dynamism fund (focusing on startups in national security and defense), and separate funds of about $1.7 billion for investments in applied technologies and infrastructure projects, with $700 million allocated for biotech and healthcare, among other sectors. Andreessen Horowitz's management emphasizes a strategic focus on technologies that enhance America's technological leadership — from artificial intelligence and cryptocurrencies to defense, education, and biomedicine. Industry estimates suggest that the total capital managed by a16z now constitutes about 18% of all venture investments made in the U.S. last year. The emergence of this new mega fund during a period when 2025 was the quietest year for fundraising since 2017 indicates a return of confidence — investors are willing to entrust record amounts to proven players in pursuit of “the next big ideas” among startups.
Investment Boom in AI Continues
The artificial intelligence sector remains the main magnet for venture capital in 2026. Following last year’s hype, interest in AI startups is unabated: during the first weeks of the new year, super-sized deals are being recorded even at early stages. For instance, last week, the startup lab Humans&, founded by a team of top researchers from Google, OpenAI, Anthropic, and Meta, raised about $480 million in seed investment — an unprecedented amount for such an early stage. Another example is Ricursive Intelligence, an ambitious project in advanced AI, which announced a $300 million Series A round at an estimated valuation of around $4 billion. Projects led by well-known entrepreneurs are also drawing attention: the new startup Merge Labs, founded by OpenAI co-founder Sam Altman and developing brain-computer interfaces integrating AI, reportedly secured around $252 million in initial funding. In total, according to Crunchbase, over 40% of all investments at the seed and Series A stages in 2026 are already accounted for by rounds worth $100 million and above — a previously rare occurrence, made possible in large part due to the race for AI. Venture investors continue to see AI as a key growth area and are ready to compete for the most promising teams. The competition for talent and cutting-edge developments in AI remains high, and startups continue to receive large checks to scale solutions in generative AI, speech, and visual algorithms, process automation, and other fields.
New “Unicorns” in Defense Technologies and AI
A series of major deals at the start of the year has expanded the ranks of “unicorns” — private companies valued at over $1 billion. Several startups achieved this status thanks to funding rounds:
- Deepgram (USA, voice AI) – raised $130 million in a Series C round at a valuation of approximately $1.3 billion, becoming a leader in the AI voice technology segment.
- Harmattan AI (France, AI-based defense systems) – secured around $200 million in a Series B round, raising the Parisian startup's valuation to $1.4 billion. Harmattan AI has become a rare unicorn in the strategically important field of defense technologies for Europe.
- Defense Unicorns (USA, secure software for government agencies) – closed a $136 million Series B round led by Bain Capital, achieving a valuation of over $1 billion. The company lived up to its name by entering the unicorn club amid rapid revenue growth from contracts with the Pentagon.
The emergence of these new high-valued players reflects the increasing focus of venture capital on projects related to artificial intelligence and national security. In line with the trend set by funds like a16z American Dynamism, investors are actively financing companies engaged in both commercial AI products (like voice assistants for businesses) and technologies of governmental significance (defense, cybersecurity). Moreover, this venture race is global: the formation of new unicorns involves not only Silicon Valley but also Europe, Asia, and other regions where technology companies with billion-dollar valuations are emerging.
Tech Giants Hunt for AI Startups
Not only venture funds but also the largest corporations are striving to strengthen their positions in the field of artificial intelligence. A notable example is Apple, which executed one of its largest deals in recent years by agreeing to acquire the Israeli AI startup Q.ai, specializing in AI-based audio technologies. According to insiders, the acquisition was valued at around $1.6 billion, making it the second-largest purchase in Apple's history (after the acquisition of Beats). The startup Q.ai develops machine learning systems for whisper speech recognition and sound improvement in challenging environments, and its team of approximately 100 specialists will join Apple. The deal underscores how intense the competition has become among Big Tech for breakthrough AI developments: companies like Apple, Google, Microsoft, and Meta are actively acquiring promising projects to stay ahead in the AI technology race. For startups and their investors, such exits serve as proof of the validity of high valuations: major strategic players are willing to pay billions for access to cutting-edge solutions and talents in the field of AI.
Multi-Million Rounds in Biotech Signal Revival
The biotechnology sector is also keeping pace: in January, several biotech startups announced large funding rounds, signaling a resurgence of investor interest in healthcare. The most notable deal was a $305 million Series F round for Parabilis Medicines of Massachusetts (formerly known as FogPharma). The raised capital will allow Parabilis to advance its experimental cancer drug (peptide zolucatetide) into pivotal clinical trial phases and also expand its peptide delivery platform technology for new drug development. Notably, Parabilis has already raised venture financing six times while remaining a private company longer than the industry average. Such a large late-round from well-known investors (including public market funds) indicates strong confidence in the prospects of its scientific developments.
Another significant case is California startup Soley Therapeutics, which raised about $200 million in a Series C round. The company employs artificial intelligence and computational biology technologies to discover new cancer treatment methods and will direct the funds toward advancing two of its candidates to clinical trial stages. Records are also occurring at earlier stages: for instance, the very young biotech company AirNexis Therapeutics received $200 million in seed funding (Series A) to develop an innovative drug for lung diseases. Such an investment amount at the A stage is quite rare, indicating high confidence in the project's developments: AirNexis has licensed a promising molecule from the Chinese pharmaceutical company Haisco and plans to bring it to the global market for treating COPD (asthma and chronic obstructive pulmonary disease).
In addition to these mega rounds, there’s a string of more moderate deals: industry observers reported that in January, at least half a dozen biotech startups attracted between $50 million to $100 million each. All this points to a revived interest in biotech after a challenging few years: venture funds are actively financing companies in pharmaceuticals and medicine, especially if the startup possesses breakthrough science or a market-ready product. Major crossover investors (funds that operate in both private and public markets) are returning to biotech, setting the stage for a resumption of IPOs, provided the market conditions are favorable.
New Specialized Venture Funds Emerging Worldwide
In addition to financing startups, capital is also actively flowing into the ecosystem through new venture funds, often focused on narrow niches or strategic themes. The startup industry is diversifying, as evidenced by the emergence of specialized funds in various regions at the beginning of 2026. Here are a few notable examples:
- All Aboard Alliance (Global) – a coalition of private venture firms, including Bill Gates' Breakthrough Energy Ventures, announced the formation of a $300 million fund to invest in startups related to climate change and greenhouse gas emission reduction. Initial investments are planned to be made this year, reflecting growing interest in climate tech.
- 2150 VC (Europe) – the London-Copenhagen venture fund 2150 closed its second fund of €210 million, bringing total assets under management to €500 million. The funds will support startups developing sustainable urban development technologies (urban climate solutions, green construction and infrastructure projects).
- VZVC (USA) – a new venture firm founded by former a16z partner Vidya Pandya, is forming its debut fund, estimated at $400 million, to invest at the intersection of artificial intelligence and digital health. This example illustrates a trend where experienced investors leave large funds to focus on quickly growing niche areas.
- NUS Venture Fund (Asia) – the National University of Singapore launched a $120 million venture fund to support its own spin-off startups and university research. This public-private initiative aims to commercialize innovations in academic science and strengthen the local startup ecosystem.
Alongside the mentioned examples, corporate and regional development funds continue to emerge. Large corporations and governments are increasingly participating in the venture ecosystem by creating funds to support priority sectors — from climate technologies and biomedicine to defense and artificial intelligence. As a result, the landscape of venture capital is becoming ever more diverse: alongside billion-dollar mega funds, compact targeted funds coexist. For startups, this means more opportunities to secure funding worldwide, including in segments that were once deemed exotic for venture capital.
Expectations and Outlook: IPOs and Continued Market Growth
Such an active start to the year fosters cautious optimism among venture market players regarding forecasts for 2026. On one hand, record funding rounds and the emergence of new funds provide startups with access to capital. On the other, investors will scrutinize the effectiveness of their investments and the development of portfolio companies more closely. A key indicator of sentiment could be the revival of IPOs. After a quiet few years, with only a handful of notable tech IPOs occurring in 2025, 2026 is expected to see a lineup of unicorns ready to take their chances in the public market, should market conditions improve.
Venture funds are already preparing potential IPO candidates. Rumors are swirling about plans for a number of major AI and fintech companies from Silicon Valley, along with certain biotech firms that have attracted crossover investors at late stages, to go public. Among the most anticipated in the industry are the potential IPOs of giants like OpenAI, Anthropic, or even the space company SpaceX — their listings could invigorate the market and attract broader public attention. The high valuations that startups obtained in their recent rounds imply expectations for a swift exit — either via strategic sale or through public listing.
At the same time, the volume of available "dry powder" — that is, uninvested funds in venture capital — remains substantial. According to PitchBook, only impact investment funds currently control over $200 billion in unallocated capital, while the total global venture dry powder is measured in the hundreds of billions of dollars. These capital reserves can sustain a high pace of funding for innovations even amid changing economic circumstances, creating competition for the best deals.
Of course, specific risks remain: rising interest rates, geopolitical instability, and stock market volatility could temper investors' risk appetites. Nevertheless, at this moment, the startup ecosystem enters the new year with a solid buffer and cautious optimism. Venture investors and company founders hope that 2026 will be a period of further growth — provided there are reasonable project valuations and a favorable macroeconomic environment.
